Common use of EFFECTIVE AND BINDING AGREEMENT Clause in Contracts

EFFECTIVE AND BINDING AGREEMENT. Halifax and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s obligations under this CIA based on a certification by Halifax that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax is relieved of its CIA obligations, Halifax will be required to notify OIG in writing at least 30 days in advance if Halifax plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax CHSI and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxCHSI’s obligations under this CIA based on a certification by Halifax CHSI that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax CHSI is relieved of its CIA obligations, Halifax CHSI will be required to notify OIG in writing at least 30 days in advance if Halifax CHSI plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax CHSI signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /Community Health Systems, Inc. Corporate Integrity Agreement /s/ ▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇ July 23, 2014 ▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /Sr. Vice President, Corporate Compliance and Privacy Officer /s/ ▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇ July 23, ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ , Esq. DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax CHSI Community Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /Systems, Inc. Corporate Integrity Agreement /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇ July 28, 2014 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services //s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ July 24, 2014 ▇/ 3/9/2014 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Community Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services Systems, Inc. Corporate Integrity Agreement This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax RMC and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of RMC. B. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. D. OIG may agree to a suspension of HalifaxRMC’s obligations under this CIA based on a certification by Halifax RMC that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax RMC is relieved of its CIA obligations, Halifax RMC will be required to notify OIG in writing at least 30 days in advance if Halifax RMC plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. E. The undersigned Halifax RMC signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Senior Vice President and General Counsel Rural/Metro Corporation 6/14/12 DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇/ ▇/ 3/10/14 ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇▇▇▇, LLP Counsel for Rural/Metro Corporation 6/14/12 DATE /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/10/14 6/14/12 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ DATE & ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇, LLP Counsel for Rural/Metro Corporation DATE /▇▇▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ . ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇. ▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Chief Counsel for Halifax to the Inspector General Office of Inspector General U. S. Department of Health and Human Services 6/15/12 DATE /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services 6/15/12 DATE Rural/Metro Corporation Corporate Integrity Agreement May 9, 2012 This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax CCH and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxCCH’s obligations under this CIA based on a certification by Halifax CCH that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax CCH is relieved of its CIA obligations, Halifax CCH will be required to notify OIG in writing at least 30 days in advance if Halifax it plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modifiedmodified as to CCH. D. The undersigned Halifax signatories for CCH represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇/ 1-26-15 ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ DATE Chief Executive Officer /▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇/ 1/26/15 ▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Member /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 1/30/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 1/27/15 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Dignity Health and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxDignity Health’s obligations under this CIA based on a certification by Halifax Dignity Health that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Dignity Health is relieved of its CIA obligations, Halifax will Dignity Health shall be required to notify OIG in writing at least 30 days in advance if Halifax Dignity Health plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax Dignity Health signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇▇/ 10.29.14 ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ DATE Sr. Executive Vice President Chief Financial Officer Dignity Health /Raja ▇.▇. ▇▇▇▇▇▇▇/ 29 October 2014 RAJA ▇.▇. ▇▇▇▇▇▇▇ DATE V.P. & Chief Executive Officer Halifax Associate General Counsel for Regulatory Affairs Dignity Health /▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇/ 3/10/14 10/29/14 ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center Corporate Compliance Officer Dignity Health /▇. ▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. Oct. 29, 2014 ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇ DATE ▇▇▇▇ & ▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Dignity Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 10/30/2014 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇/ 3/10/2014 10-29-2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇ DATE Associate Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA. A. IRO Engagement 1. Dignity Health shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.11 of the CIA or any additional information submitted by Dignity Health in response to a request by OIG, whichever is later, OIG will notify Dignity Health if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Dignity Health may continue to engage the IRO. 2. If Dignity Health engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, Dignity Health shall submit the information identified in Section V.A.11 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Dignity Health at the request of OIG, whichever is later, OIG will notify Dignity Health if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Dignity Health may continue to engage the IRO.

EFFECTIVE AND BINDING AGREEMENT. Halifax Orbit and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxOrbit’s obligations under this CIA based on a certification by Halifax Orbit that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax is relieved of its CIA obligations, Halifax will be required to notify OIG in writing at least 30 days in advance if Halifax Orbit plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax Orbit signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇/ 5/11/15 ▇▇▇▇▇▇▇ ▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health Orbit Medical, Inc. /▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇/ 3/10/14 ▇./ 5/12/15 ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /, ▇▇. DATE ▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 5/15/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇ ▇. ▇▇▇▇▇/ 5-12-2015 ▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Progenity and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxProgenity’s obligations under this CIA based on a certification by Halifax Progenity that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Progenity is relieved of its CIA obligations, Halifax will Progenity shall be required to notify OIG in writing at least 30 days in advance if Halifax Progenity plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Progenity’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Progenity signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies or facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. //s/ ▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇ July 21, 2020 ▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. Counsel, Progenity /s/ ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇ July 21, 2020 ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE ▇. ▇▇▇▇▇▇▇ Day ▇▇▇▇▇▇, ▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP Counsel for Progenity /s/ ▇▇▇▇ ▇. Re July 20, 2020 ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services //s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /July 21, 2020 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax KDMC and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxKDMC’s obligations under this CIA based on a certification by Halifax KDMC that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax KDMC is relieved of its CIA obligations, Halifax KDMC will be required to notify OIG in writing at least 30 days in advance if Halifax KDMC plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax KDMC signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ President/CEO of King’s Daughters Health System DATE 5/16/14 /▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇▇▇▇ Counsel for King’s Daughters Medical Center ▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ & ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ , PLLC DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health 5/16/14 /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 5/27/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services DATE /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE ‌ Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services 5/21/14 APPENDIX A INDEPENDENT REVIEW ORGANIZATIONS This Appendix contains the requirements relating to the Legal Independent Review Organization Organizations (Legal IROIROs) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Parkland and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of Parkland. B. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG ▇. ▇▇▇ may agree to a suspension of HalifaxParkland’s obligations under this CIA based on a certification by Halifax Parkland that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Parkland is relieved of its CIA obligations, Halifax Parkland will be required to notify OIG in writing at least 30 days in advance if Halifax Parkland plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. E. The undersigned Halifax Parkland signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇/ 3/10/14 ▇▇▇▇ 5/24/13 ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇▇ DATE Interim Chief Executive Officer Parkland Health and Hospital System /▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇5/24/13 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇, MS, CPA, CHC DATE Sr. Vice President/Chief Compliance and Ethics Officer Parkland Health and Hospital System /▇▇▇▇ ▇. ▇▇▇▇▇▇/ 5/24/13 ▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE General Counsel Halifax Parkland Health and Hospital Medical Center System /▇. ▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 5/28/13 ▇. ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ and ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ , LLP Counsel for Halifax Health Parkland /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 5/30/13 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /Berlin/ 5/28/13 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ BERLIN DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 5/28/13 ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains Services A. Billing IRO Engagement 1. Parkland shall engage a Billing IRO that possesses the requirements relating qualifications set forth in Paragraph B, below, to perform the Legal Independent Review Organization (Legal responsibilities in Paragraph C, below. The Billing IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.14 of the CIA or any additional information submitted by Parkland in response to a request by OIG, whichever is later, OIG will notify Parkland if the IRO is unacceptable. Absent notification from OIG that the Billing IRO is unacceptable, Parkland may continue to engage the Billing IRO) required by Section III.E . 2. If Parkland engages a new Billing IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new Billing IRO is engaged, Parkland shall submit the information identified in Section V.A.14 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Parkland at the request of OIG, whichever is later, OIG will notify Parkland if the IRO is unacceptable. Absent notification from OIG that the Billing IRO is unacceptable, Parkland may continue to engage the IRO.

EFFECTIVE AND BINDING AGREEMENT. Halifax Rehab and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxRehab’s obligations under this CIA based on a certification by Halifax Rehab that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Rehab is relieved of its CIA obligations, Halifax Rehab will be required to notify OIG in writing at least 30 days in advance if Halifax Rehab plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax Rehab signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 5/11/15 ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Rehab Medical Center /▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇/ 3/10/14 5/12/15 ▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ , ▇▇. DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 5/15/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇ ▇. ▇▇▇▇▇/ 5-12-2015 ▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ ▇▇▇▇▇ and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s ▇▇▇▇▇’▇ obligations under this CIA based on a certification by Halifax ▇▇▇▇▇ that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax ▇▇▇▇▇ is relieved of its CIA obligations, Halifax will ▇▇▇▇▇ shall be required to notify OIG in writing at least 30 days in advance if Halifax ▇▇▇▇▇ plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) ▇▇▇▇▇’▇ responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax ▇▇▇▇▇ signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ON BEHALF OF ▇▇▇▇▇▇/ 3/10/14 ‌ /▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇, ESQ. ▇▇▇▇ ▇▇▇General Counsel ▇▇▇▇▇ Healthcare DATE ▇▇▇▇Counsel for ▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ Healthcare Polsinelli DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌ /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. ▇▇▇▇▇ shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D.‌ Within 30 days after OIG receives the information identified in Section V.A.9 of the CIA or any additional information submitted by ▇▇▇▇▇ in response to a request by OIG, whichever is later, OIG will notify ▇▇▇▇▇ if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, ▇▇▇▇▇ may continue to engage the IRO. 2. If ▇▇▇▇▇ engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, ▇▇▇▇▇ shall submit the information identified in Section V.A.9 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by ▇▇▇▇▇ at the request of OIG, whichever is later, OIG will notify ▇▇▇▇▇ if the IRO is unacceptable.‌ Absent notification from OIG that the IRO is unacceptable, ▇▇▇▇▇ may continue to engage the IRO. B. IRO Qualifications The IRO shall:‌‌ 1. assign individuals to conduct the Arrangements Review who are knowledgeable in the requirements of the Anti-Kickback Statute and the ▇▇▇▇▇ Law and the regulations and other guidance documents related to these statutes; and‌ 2. have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis.‌ C. IRO Responsibilities The IRO shall:‌‌ 1. perform each Arrangements Review in accordance with the specific requirements of the CIA;‌ 2. respond to all OIG inquires in a prompt, objective, and factual manner; and 3. prepare timely, clear, well-written reports that include all the information required by Appendix B to the CIA.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ Prime and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxPrime’s obligations under this CIA based on a certification by Halifax Prime that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Prime is relieved of its CIA obligations, Halifax will Prime shall be required to notify OIG in writing at least 30 days in advance if Halifax Prime plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Prime’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Prime signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA.CIA.‌‌ E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. ON BEHALF OF PRIME‌‌ /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 /_ _ ▇▇▇▇ ▇▇▇▇▇▇ DATE , M.D. Chairman, President & and Chief Executive Officer Halifax Health /▇Prime Healthcare Services, Inc. DATE Vice President & General Counsel Prime Healthcare Services, Inc. Prime Healthcare Foundation, Inc. Prime Healthcare Management, Inc. _ 5/19/21 DATE ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Prime Healthcare ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌‌ /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇_ 5/26/2021 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. Prime shall engage an IRO to perform the Claims Review and Inpatient Medical Necessity Review that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the Claims Review and Inpatient Medical Necessity Review in a professionally independent and objective fashion, as set forth in Paragraph E.‌ 2. Prime shall engage an IRO to perform the Arrangements Review that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall not have a prohibited relationship to Prime as set forth in Paragraph F.‌ 3. Within 30 days after OIG receives the information identified in Section

EFFECTIVE AND BINDING AGREEMENT. Halifax ▇▇▇▇▇▇▇ and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s ▇▇▇▇▇▇▇’▇ obligations under this CIA based on a certification by Halifax ▇▇▇▇▇▇▇ that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax ▇▇▇▇▇▇▇ is relieved of its CIA obligations, Halifax will ▇▇▇▇▇▇▇ shall be required to notify OIG in writing at least 30 days in advance if Halifax ▇▇▇▇▇▇▇ plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) ▇▇▇▇▇▇▇’▇ responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax ▇▇▇▇▇▇▇ signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ Chief Financial Officer DATE ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ , ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ & ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇, P.C. Counsel for ▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Vanguard and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s Vanguard's obligations under this CIA based on a certification by Halifax Vanguard that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-31320a- 3, in any entity that bills any Federal health care program. If Halifax Vanguard is relieved of its CIA obligations, Halifax will Vanguard shall be required to notify OIG in writing at least 30 days in advance if Halifax Vanguard plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Vanguard's responsibility to follow all applicable Federal health care program requirements or (2) the government's right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Vanguard signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically- transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇/ 3/10/14 _12/11/18 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇ DATE President and Chief Executive Officer /▇▇▇▇ ▇. ▇▇▇Re/ 12/13/2018 ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/10/2014 1/9/2019 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Associate Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.Services

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ ResMed and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxResMed’s obligations under this CIA based on a certification by Halifax ResMed that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax ResMed is relieved of its CIA obligations, Halifax will ResMed shall be required to notify OIG in writing at least 30 days in advance if Halifax ResMed plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) ResMed’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax ResMed signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health // ▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇ Secretary DATE ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Day Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ ResMed Corp. DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. ResMed shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall not have a prohibited relationship to ResMed as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.9 of the CIA or any additional information submitted by ResMed in response to a request by OIG, whichever is later, OIG will notify ResMed if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, ResMed may continue to engage the IRO.‌ 2. If ResMed engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, ResMed shall submit the information identified in Section V.A.9 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by ResMed at the request of OIG, whichever is later, OIG will notify ResMed if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, ResMed may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ Post Acute Medical and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxPost Acute Medical’s obligations under this CIA based on a certification by Halifax Post Acute Medical that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Post Acute Medical is relieved of its CIA obligations, Halifax will Post Acute Medical shall be required to notify OIG in writing at least 30 days in advance if Halifax Post Acute Medical plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Post Acute Medical’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Post Acute Medical signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ . ▇▇▇▇▇▇▇▇/ 3/10/14 8/13/18 ‌‌ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇ DATE Manager of Post Acute Medical Principal, President, and CEO, Post Acute Medical, LLC /▇▇▇▇ ▇. ▇▇▇Re/ 8/10/2018 ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 8/13/18 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax The DIG Entities and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s the DIG Entities’ obligations under this CIA based on a certification by Halifax the DIG Entities that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax is the DIG Entities are relieved of its their CIA obligations, Halifax the DIG Entities will be required to notify OIG in writing at least 30 days in advance if Halifax plans the DIG Entities plan to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax DIG Entities signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇▇/ 3/10/14 2/18/14 ▇▇▇▇ ▇▇▇▇▇▇▇ DATE Executive Vice President & Chief Executive and Compliance Officer Halifax Health Diagnostic Imaging Group, LLC /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 , M.D./ 2/18/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ , M.D. DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇President ▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Diagnostic Imaging Services, P.C. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 2/19/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇/ 3/10/2014 2/18/14 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax The U.S. Healthcare Parties and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s the U.S. Healthcare Parties’ obligations under this CIA based on a certification by Halifax the U.S. Healthcare Parties that it is they are no longer providing health care items or services that will be billed to any Federal health care program and that it does they do not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax is the U.S. Healthcare Parties are relieved of its their CIA obligations, Halifax will the U.S. Healthcare Parties shall be required to notify OIG in writing at least 30 days in advance if Halifax plans the U.S. Healthcare Parties plan to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) the U.S. Healthcare Parties’ responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax signatories for the U.S. Healthcare Parties and the ▇▇▇▇▇ Entities represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇. ▇▇▇▇▇/ 3/10/14 8/25/2016 ▇▇▇ ▇. ▇▇▇▇▇ DATE On behalf of U.S. Healthcare Supply, LLC, Spectrum Diabetic Services, LLC, Heritage Diabetic Supply, Inc, and Dependable Diabetic Supply, LLC /▇▇▇ ▇. ▇▇▇▇▇/ 8/25/2016 ▇▇▇ ▇. ▇▇▇▇▇ DATE On behalf of U.S. Diagnostics, NJ /▇▇▇ ▇. ▇▇▇▇▇/ 8/25/2016 ▇▇▇ ▇. ▇▇▇▇▇ DATE Individually /▇▇▇▇▇▇ ▇. ▇▇▇▇▇/ 8/25/2016 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health On behalf of U.S. Diagnostics, Inc. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇/ 8/25/2016 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇ DATE Individually /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ ▇▇./ 8/29/2016 ▇▇▇▇▇▇ ▇/ 3/10/14 . ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ . DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇Procter LLP Counsel for U.S. Healthcare Supply, LLC, Spectrum Diabetic Services, LLC, Heritage Diabetic Supply, Inc; Dependable Diabetic Supply, LLC; U.S. Diagnostics, Inc., U.S. Diagnostics NJ; ▇▇▇▇▇▇ Will & ▇. ▇▇▇▇▇; and ▇▇▇ ▇. ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌ /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 8/30/2016 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 8/30/2016 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ▇▇▇▇▇ and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxVibra’s obligations under this CIA based on a certification by Halifax Vibra that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Vibra is relieved of its CIA obligations, Halifax will Vibra shall be required to notify OIG in writing at least 30 days in advance if Halifax Vibra plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Vibra’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Vibra signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇ DATE Chief Executive Officer ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇, ESQ. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 , ESQ. Counsel for Vibra ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇ DATE Senior Counsel ▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax PALMS and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by prior written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxPALMS’s obligations under this CIA based on a certification by Halifax PALMS that it is no longer providing health care items or services that will be billed to any Federal health care program programs and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, interest in any entity that bills any Federal health care program. If Halifax PALMS is relieved of its CIA obligations, Halifax will PALMS shall be required to notify OIG in writing at least 30 days in advance if Halifax PALMS plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, the OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to, and do not affect (1) PALMS’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable program requirements. E. The undersigned Halifax PALMS signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇▇/ 2-14-2014 ▇▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health ▇▇▇▇▇▇▇, co-owner Date /▇▇▇▇▇▇ ▇▇▇▇▇▇▇/ 2-14-2014 ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, co-owner Date /▇. ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇/ 2-17-2014 ▇. ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital for PALMS Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Transport, L.L.C. Date /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 2/20/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 2/20/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE , Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement 1. PALMS shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by PALMS in response to a request by OIG, whichever is later, OIG will notify PALMS if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, PALMS may continue to engage the IRO. 2. If PALMS engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, PALMS shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information, or any additional information submitted by PALMS at the request of OIG, whichever is later, OIG will notify PALMS if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, PALMS may continue to engage the IRO.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ WBH and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxWBH’s obligations under this CIA based on a certification by Halifax WBH that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax WBH is relieved of its CIA obligations, Halifax will WBH shall be required to notify OIG in writing at least 30 days in advance if Halifax WBH plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) WBH’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Beaumont Health and WBH signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ Senior Vice President and General Counsel Beaumont Health ▇▇▇▇▇ Lovells US LLP Counsel for Beaumont Health DATE Senior Counsel ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Office of Inspector General U. S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. WBH shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall not have a prohibited relationship to WBH as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by WBH in response to a request by OIG, whichever is later, OIG will notify WBH if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, WBH may continue to engage the IRO.‌ 2. If WBH engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, WBH shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by WBH at the request of OIG, whichever is later, OIG will notify WBH if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, WBH may continue to engage the IRO.‌ B. IRO Qualifications The IRO shall:‌‌ 1. assign individuals to conduct the Arrangements Review who are knowledgeable in the requirements of the Anti-Kickback Statute and the ▇▇▇▇▇ Law and the regulations and other guidance documents related to these statutes;‌ 2. possess expertise in fair market valuation issues or have the ability to associate a valuation firm to assist in conducting the transactions review component of the Arrangements Review; and‌ 3. have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis.‌ C. IRO Responsibilities The IRO shall:‌‌‌‌ 1. perform each Arrangements Review in accordance with the specific requirements of the CIA;‌ 2. respond to all OIG inquires in a prompt, objective, and factual manner; and 3. prepare timely, clear, well-written reports that include all the information required by Appendix B to the CIA.‌ D. WBH Responsibilities‌ WBH shall ensure that the IRO has access to all records and personnel necessary to complete the reviews listed in Section III.E of this CIA and that all records furnished to the IRO are accurate and complete.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ FHS and ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s FHS obligations under this CIA based on a certification by Halifax FHS that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax FHS is relieved of its CIA obligations, Halifax will FHS shall be required to notify OIG in writing at least 30 days in advance if Halifax FHS plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. ▇. ▇▇▇ may agree to a suspension of ▇▇▇▇▇ ▇▇▇▇▇▇▇▇’▇ obligations under this CIA based on a certification by ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ that he does not have any ownership or control interest, as defined in 42 U.S.C. §1320a-3, in any entity that bills any Federal health care programs. If ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ is relieved of his CIA obligations, he shall be required to notify OIG in writing at least 30 days in advance if he plans to obtain an ownership or control interest in any entity that bills any Federal health care programs. At such time, OIG shall evaluate whether the CIA shall be reactivated or modified. E. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) FHS’s and/or ▇▇▇▇▇ ▇▇▇▇▇▇▇▇’▇ responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. F. The undersigned Halifax FHS and/or ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. G. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services ‌‌‌‌‌‌‌‌‌‌‌ ‌‌‌‌‌‌‌‌‌‌‌‌‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. FHS shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.7 of the CIA or any additional information submitted by FHS in response to a request by OIG, whichever is later, OIG will notify FHS if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, FHS may continue to engage the IRO.‌ 2. If FHS engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, FHS shall submit the information identified in Section V.A.7 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by FHS at the request of OIG, whichever is later, OIG will notify FHS if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, FHS may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ CRMC and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA.CIA.‌‌ B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxCRMC’s obligations under this CIA based on a certification by Halifax CRMC that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax CRMC is relieved of its CIA obligations, Halifax will CRMC shall be required to notify OIG in writing at least 30 days in advance if Halifax CRMC plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) CRMC’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax CRMC signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. ON BEHALF OF CRMC‌‌ /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /Cookeville Regional Medical Center DATE ▇▇▇▇▇▇▇, ▇▇▇▇▇▇ & ▇▇▇▇▇, PC DATE ▇.▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ , ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇, ▇▇▇▇▇▇ DATE & ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ , LLP Counsel for Halifax Health DATE ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌‌ /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌‌‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. CRMC shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall not have a prohibited relationship to CRMC as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by CRMC in response to a request by OIG, whichever is later, OIG will notify CRMC if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, CRMC may continue to engage the IRO.‌ 2. If CRMC engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, CRMC shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by CRMC at the request of OIG, whichever is later, OIG will notify CRMC if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, CRMC may continue to engage the IRO.‌ B. IRO Qualifications The IRO shall:‌‌ 1. assign individuals to conduct the Arrangements Review who are knowledgeable in the requirements of the Anti-Kickback Statute and the ▇▇▇▇▇ Law and the regulations and other guidance documents related to these statutes;‌ 2. possess expertise in fair market valuation issues or have the ability to associate a valuation firm to assist in conducting the transactions review component of the Arrangements Review; and‌ 3. have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis.‌ C. IRO Responsibilities The IRO shall:‌ 1. perform each Arrangements Review in accordance with the specific requirements of the CIA;‌‌‌‌ 2. respond to all OIG inquires in a prompt, objective, and factual manner; and 3. prepare timely, clear, well-written reports that include all the information required by Appendix B to the CIA.‌ D. CRMC Responsibilities‌ CRMC shall ensure that the IRO has access to all records and personnel necessary to complete the reviews listed in Section III.E of this CIA and that all records furnished to the IRO are accurate and complete.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ Bhayani and OIG agree as follows: A. This CIA IA shall become final and binding on the date the final signature is obtained on the CIAIA. B. This CIA IA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIAIA. C. OIG may agree to a suspension of HalifaxBhayani’s obligations under this CIA IA based on a certification by Halifax Bhayani that it Bhayani is no longer providing health care items or services that will be billed to any Federal health care program and that it Bhayani does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Bhayani is relieved of its CIA Bhayani’s IA obligations, Halifax will Bhayani shall be required to notify OIG in writing at least 30 days in advance if Halifax Bhayani plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA IA will be reactivated or modified. D. All requirements and remedies set forth in this IA are in addition to and do not affect: (1) Bhayani’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements.‌‌ E. The undersigned Halifax Bhayani signatories represent represents and warrant warrants that they are Bhayani is authorized to execute this CIAIA. The undersigned OIG signatories represent that they are signing this CIA IA in their official capacity and that they are authorized to execute this CIAIA. E. F. This CIA IA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIAIA. Facsimiles Electronically transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIAIA. ON BEHALF OF BHAYANI‌ /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇/ 12/18/19 ‌‌ ▇/ 3/10/14 ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ , M.D. DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇/ ‌ ▇/ 3/10/14 ▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ , M.D., on behalf of DATE New York Otolaryngology & Aesthetic Surgery P.C., and NYC Metro Ent. P.C. /▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 12/20/19 ‌‌‌ ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇ ▇. ▇▇▇▇▇ LLP Counsel for ▇▇▇▇▇▇▇▇ ▇/ 3/7/2014 ▇▇▇▇▇▇, M.D., New York Otolaryngology & Aesthetic Surgery P.C., and NYC Metro Ent. P.C. ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌ ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health and Human Services ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.C of the CIAIA. A. IRO Engagement‌ 1. Bhayani shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.2 of the IA or any additional information submitted by Bhayani in response to a request by OIG, whichever is later, OIG will notify Bhayani if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Bhayani may continue to engage the IRO.‌ 2. If Bhayani engages a new IRO during the term of the IA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Bhayani shall submit the information identified in Section V.A.2 of the IA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information, or any additional information submitted by Bhayani at the request of OIG, whichever is later, OIG will notify Bhayani if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Bhayani may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax CSI and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxCSI’s obligations under this CIA based on a certification by Halifax CSI that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax CSI is relieved of its CIA obligations, Halifax will CSI shall be required to notify OIG in writing at least 30 days in advance if Halifax CSI plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) CSI’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax CSI signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇_/s/ ▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /Ward____________________ __6/28/16___________________ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇DATE Chairman of the Board, Interim Chief Executive Officer and President _/s/ ▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /Loucks________________ __6/28/16___________________ ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Skadden, Arps, Slate, ▇▇/ 3/10/14 ▇▇▇▇▇ & ▇▇▇▇, LLP __/s/ ▇▇▇▇▇▇ ▇. Deconti______________ ____6/23/16____________ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /_/s/ ▇▇▇▇▇ ▇. Ellis________________________ _____6/24/16___________ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Avanti and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s Avanti's obligations under this CIA based on a certification by Halifax Avanti that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Avanti is relieved of its CIA obligations, Halifax will Avanti shall be required to notify OIG in writing at least 30 days in advance if Halifax Avanti plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Avanti's responsibility to follow all applicable Federal health care program requirements or (2) the government's right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Avanti signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇/ 3/10/14 11-7-18 ‌‌ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ DATE President & Interim Chief Executive Officer Halifax Avanti Hospitals, LLC /▇▇▇▇▇ ▇▇▇▇▇/ 11/15/18 ‌‌ ▇▇▇▇▇ ▇▇▇▇▇ DATE Chief Executive Officer Gardena Hospital, L.P. /▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇/ 11/20/18 ‌‌ ▇▇▇▇▇▇▇ ▇▇▇▇▇ DATE ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ Counsel for Gardena Hospital, L.P. and Avanti Hospitals, LLC /▇▇▇▇ ▇. Re/ 11/05/2018 ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 11/1/2018 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the ill.E ofthe CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Amedisys and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxAmedisys’s obligations under this CIA based on a certification by Halifax Amedisys that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Amedisys is relieved of its CIA obligations, Halifax Amedisys will be required to notify OIG in writing at least 30 days in advance if Halifax Amedisys plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax Amedisys signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA.. Amedisys, Inc. and Amedisys Holding, LLC Corporate Integrity Agreement E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /Amedisys, Inc. and Amedisys Holding, LLC Corporate Integrity Agreement /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ 4.22.14 ▇/ 3/10/14 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE President and Interim Chief Executive Officer On behalf of Amedisys, Inc. /s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇ 4.22.14 ▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE King & Spalding, LLP Counsel for Amedisys, Inc. Amedisys, Inc. and Amedisys Holding, LLC Corporate Integrity Agreement /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ 4.22.14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE President and Interim Chief Executive Officer On behalf of Amedisys Holding, LLC /s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇ 4.22.14 ▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE King & Spalding, LLP Counsel for Amedisys Holding, LLC Amedisys, Inc. and Amedisys Holding, LLC Corporate Integrity Agreement ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ 4.22.14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services //s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /4.22.14 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health Amedisys, Inc. and Human Services Amedisys Holding, LLC Corporate Integrity Agreement This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax The Friendship Entities and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s the Friendship Entities’ obligations under this CIA based on a certification by Halifax the Friendship Entities that it is they are no longer providing health care items or services that will be billed to any Federal health care program and that it does they do not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax is the Friendship Entities are relieved of its their CIA obligations, Halifax will the Friendship Entities shall be required to notify OIG in writing at least 30 days in advance if Halifax plans the Friendship Entities plan to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) the Friendship Entities’ responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax the Friendship Entities signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. Friendship Home Health, Inc. DATE Friendship Home Health Agency, LLC DATE Friendship Home Healthcare, Inc. DATE Friendship Healthcare Systems, Inc. DATE Friendship HealthCare System DATE /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇/ Friendship Residential Services, Inc. DATE DATE DATE DATE DATE DATE ▇/ 3/10/14 -▇-▇▇ ▇-▇-▇▇ ▇-▇-▇▇ ▇-▇-▇▇ ▇-▇-▇▇ ▇-▇-▇▇ Owner of Friendship Home Health, Inc.; Friendship Home Health Agency, LLC; Friendship Home Healthcare, Inc.; Friendship Healthcare Systems, Inc.; Friendship HealthCare System; Friendship Home Solutions, Inc.; Friendship – Angel DME, Inc.; Friendship Private Duty, Inc.; Angel Private Duty and Home Health, Inc.; Friendship Home Solutions of New Jersey, Inc.; Friendship Residential Services, Inc. ▇▇▇▇ & ▇▇▇▇▇▇▇, PLC Counsel for Friendship Home Health, Inc.; Friendship Home Health Agency, LLC; Friendship Home Healthcare, Inc.; Friendship Healthcare Systems, Inc.; Friendship HealthCare System; Friendship Home Solutions, Inc.; Friendship – Angel DME, Inc.; Friendship Private Duty, Inc.; Angel Private Duty and Home Health, Inc.; Friendship Home Solutions of New Jersey, Inc.; Friendship Residential Services, Inc. DATE DATE /▇▇▇▇▇▇ ▇. ▇▇▇▇/_ _ ▇▇▇▇▇▇ ▇. ▇▇▇▇ ▇▇▇▇ & ▇▇▇▇▇▇▇, PLC Counsel for ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ DATE /▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇/_ ▇▇▇▇▇▇ ▇. ▇▇▇▇ ▇▇▇▇ & ▇▇▇▇▇▇▇, PLC Counsel for ▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇ ▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇ ▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services 5/29/15 6/1/2015 This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax DaVita and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxDaVita’s obligations under this CIA based on a certification by Halifax DaVita that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax DaVita is relieved of its CIA obligations, Halifax DaVita will be required to notify OIG in writing at least 30 days in advance if Halifax DaVita plans to resume providing health care items or services that are billed to any Federal DaVita HealthCare Partners Inc. Corporate Integrity Agreement health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax DaVita signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /DaVita HealthCare Partners Inc. Corporate Integrity Agreement /s/ ▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇ 10/21/14 ▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇Chief Compliance Officer DaVita HealthCare Partners Inc. /s/ ▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇10/21/14 ▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Legal Officer Halifax Health /DaVita HealthCare Partners Inc. /s/ ▇▇▇▇ ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇10/22/14 ▇▇▇▇ ▇. ▇▇▇▇, M.D. DATE Partner, Sidley Austin LLP /s/ ▇▇▇/ 3/10/14 ▇▇ ▇.▇. ▇▇▇▇▇ 10/22/14 ▇▇▇▇▇ ▇.▇. ▇▇▇▇▇ DATE Partner, Sidley Austin LLP DaVita HealthCare Partners Inc. Corporate Integrity Agreement 10/22/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /10/22/14 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 10/22/14 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.DaVita HealthCare Partners Inc. Corporate Integrity Agreement

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ Envision Corporate Integrity Agreement Envision and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxEnvision’s obligations under this CIA based on a certification by Halifax Envision that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Envision is relieved of its CIA obligations, Halifax will Envision shall be required to notify OIG in writing at least 30 days in advance if Halifax Envision plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Envision’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Envision signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health Envision Corporate Integrity Agreement /▇▇▇▇▇ ▇▇▇▇▇▇/ 12/15/17 ▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health General Counsel /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. 12/15/17 ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services Chief Compliance Officer /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 // 12/15/17‌ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ & ▇▇▇▇▇, P.C. Counsel to Envision, Inc. Envision Corporate Integrity Agreement /▇▇▇▇ ▇. Re/ 12/15/17 ▇▇▇▇ ▇. RE DATE Senior Counsel Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇ ▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇12/15/2017 ▇▇▇▇▇▇ ▇. ▇▇▇ ▇▇▇▇▇ DATE Associate Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services Envision Corporate Integrity Agreement This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax SNAP and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxSNAP’s obligations requirements under this CIA based on a certification by Halifax SNAP that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax SNAP is relieved of its CIA obligationsrequirements, Halifax will SNAP shall be required to notify OIG in writing at least 30 days in advance if Halifax SNAP plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) SNAP’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax SNAP signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇/ /▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌ /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Prime and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxPrime’s obligations under this CIA based on a certification by Halifax Prime that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Prime is relieved of its CIA obligations, Halifax will Prime shall be required to notify OIG in writing at least 30 days in advance if Halifax Prime plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Prime’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements.‌ E. The undersigned Halifax Prime signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. ON BEHALF OF PRIME‌‌ /▇▇▇▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health 7/31/18 ‌‌ ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌‌ /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health . Re/ 8/01/2018 /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services 8/3/18 APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA. A. IRO Engagement‌ 1. Prime shall engage an IRO(s) that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.9 of the CIA or any additional information submitted by Prime in response to a request by OIG, whichever is later, OIG will notify Prime if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Prime may continue to engage the IRO.‌ 2. If Prime engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Prime shall submit the information identified in Section V.A.9 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Prime at the request of OIG, whichever is later, OIG will notify Prime if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Prime may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax La Fuente and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by prior written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxLa Fuente’s obligations under this CIA based on a certification by Halifax La Fuente that it is no longer providing health care items or services that will be billed to any Federal health care program programs and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax La Fuente is relieved of its CIA obligations, Halifax will La Fuente shall be required to notify OIG in writing at least 30 days in advance if Halifax La Fuente plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, the OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to, and do not affect (1) La Fuente’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable program requirements. E. The undersigned Halifax La Fuente signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇/ 3/10/14 2/7/15 Date ▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health La Fuente Ocular Prosthetics, LLC /▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 2/9/2015 Date ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health La Fuente /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 3/16/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Date Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 3/4/2015 ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Date Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇3/4/2015 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Date Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Cordant and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxCordant’s obligations under this CIA based on a certification by Halifax Cordant that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Cordant is relieved of its CIA obligations, Halifax will Cordant shall be required to notify OIG in writing at least 30 days in advance if Halifax Cordant plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Cordant’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Cordant signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇7-13-2020_ ▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Sterling Healthcare Opco, LLC d/b/a Cordant Health Solutions /▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇/_ July 13, 2020 ▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Cordant /▇▇▇▇ ▇▇▇▇. ▇▇/ 3/10/14 _ 07/16/2020_ ▇▇▇▇ ▇▇▇▇▇▇ . RE DATE President & Chief Executive Officer Halifax Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /and Human Services ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ BERLIN DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 14 July 2020_ ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Good Shepherd and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxGood Shepherd’s obligations under this CIA based on a certification by Halifax Good Shepherd that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Good Shepherd is relieved of its CIA obligations, Halifax Good Shepherd will be required to notify OIG in writing at least 30 days in advance if Halifax Good Shepherd plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax Good Shepherd signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 1/29/2015 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center Manager Good Shepherd Hospice, Dallas, L.L.C. /▇. ▇▇▇▇▇ ▇▇▇▇▇▇/ 1/29/15 ▇▇/ 3/10/14 ▇. ▇▇▇ ▇▇▇▇▇▇ DATE ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP PLLC Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Good Shepherd Hospice, Dallas, L.L.C. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 2/6/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 1-29-15 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Good Shepherd and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxGood Shepherd’s obligations under this CIA based on a certification by Halifax Good Shepherd that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Good Shepherd is relieved of its CIA obligations, Halifax Good Shepherd will be required to notify OIG in writing at least 30 days in advance if Halifax Good Shepherd plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax Good Shepherd signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 1/29/2015 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center Manager Good Shepherd Hospice, Springfield, L.L.C. /▇. ▇▇▇▇▇ ▇▇▇▇▇▇ 1/29/15 ▇▇▇/ 3/10/14 ▇. ▇▇ ▇▇▇▇▇▇ DATE ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP PLLC Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Good Shepherd Hospice, Springfield, L.L.C. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 2/6/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 1/29/15 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ Providence and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxProvidence’s obligations requirements under this CIA based on a certification by Halifax Providence that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax Providence is relieved of its CIA obligationsrequirements, Halifax will Providence shall be required to notify OIG in writing at least 30 days in advance if Halifax Providence plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Providence’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Providence signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically- transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 March 15, 2022 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE‌ President and Chief Executive Officer Providence Health & Services - Washington ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA. A. IRO Engagement‌ 1. Providence shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.9 of the CIA or any additional information submitted by Providence in response to a request by OIG, whichever is later, OIG will notify Providence if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Providence may continue to engage the IRO.‌ 2. If Providence engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Providence shall submit the information identified in Section V.A.9 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Providence at the request of OIG, whichever is later, OIG will notify Providence if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Providence may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax OCOM and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxOCOM’s obligations under this CIA based on a certification by Halifax OCOM that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax OCOM is relieved of its CIA obligations, Halifax will OCOM shall be required to notify OIG in writing at least 30 days in advance if Halifax OCOM plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) OCOM’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax OCOM signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 /_ 6/29/20 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Financial Officer Halifax Health United Surgical Partners International /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇/_ 07/07/2020 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax The U.S. Healthcare Parties and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s the U.S. Healthcare Parties’ obligations under this CIA based on a certification by Halifax the U.S. Healthcare Parties that it is they are no longer providing health care items or services that will be billed to any Federal health care program and that it does they do not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax is the U.S. Healthcare Parties are relieved of its their CIA obligations, Halifax will the U.S. Healthcare Parties shall be required to notify OIG in writing at least 30 days in advance if Halifax plans the U.S. Healthcare Parties plan to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) the U.S. Healthcare Parties’ responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax signatories for the U.S. Healthcare Parties and the ▇▇▇▇▇ Entities represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ▇▇▇▇▇▇▇▇ and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax▇▇▇▇▇▇▇▇’s obligations under this CIA based on a certification by Halifax Longwood that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Longwood is relieved of its CIA obligations, Halifax will Longwood shall be required to notify OIG in writing at least 30 days in advance if Halifax Longwood plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) ▇▇▇▇▇▇▇▇’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Longwood signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 /_ 2-21-2020 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center Executive Vice President of Operations /▇. ▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇. _ 2/24/20 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & , ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health , P.C. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇Re/ 3/05/2020 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 March 3, 2020 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax IHS and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxIHS’s obligations under this CIA based on a certification by Halifax IHS that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax IHS is relieved of its CIA obligations, Halifax IHS will be required to notify OIG in writing at least 30 days in advance if Halifax IHS plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax IHS signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇/ 7/18/2014 ▇▇▇▇▇▇▇ DATE ▇▇▇▇ ▇▇▇ President & and Chief Executive Officer Halifax Health IHS DATE /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/10/14 7/18/2014 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 , ESQ. DATE ▇. ▇▇▇▇ & ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ , LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health to IHS /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 7/18/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services DATE /▇▇▇▇▇▇ ▇. ▇▇▇ ▇▇▇▇▇/ 3/9/2014 July 18, 2014 ▇▇▇▇▇▇ ▇. ▇▇▇ ▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax UMHS and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxUMHS’s obligations under this CIA based on a certification by Halifax UMHS that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax UMHS is relieved of its CIA obligations, Halifax will UMHS shall be required to notify OIG in writing at least 30 days in advance if Halifax UMHS plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) UMHS’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax UMHS signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center Vice President for Finance and Chief Financial Officer University of Missouri System The Curators of the University of Missouri, acting on behalf of the University of Missouri Health System _/▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ESQ. Norton ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ US LLP Counsel for The Curators of the University of Missouri DATE ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.Services

EFFECTIVE AND BINDING AGREEMENT. Halifax Good Shepherd and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxGood Shepherd’s obligations under this CIA based on a certification by Halifax Good Shepherd that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Good Shepherd is relieved of its CIA obligations, Halifax Good Shepherd will be required to notify OIG in writing at least 30 days in advance if Halifax Good Shepherd plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax Good Shepherd signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 1/29/2015 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center President Good Shepherd Hospice, Inc. /▇. ▇▇▇▇▇ ▇▇▇▇▇▇/ 1/29/2015 ▇▇/ 3/10/14 ▇. ▇▇▇ ▇▇▇▇▇▇ DATE ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP PLLC Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Good Shepherd Hospice, Inc. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 2/6/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 1/29/15 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax TPRC and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxTPRC’s obligations under this CIA based on a certification by Halifax TPRC that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax TPRC is relieved of its CIA obligations, Halifax will TPRC shall be required to notify OIG in writing at least 30 days in advance if Halifax TPRC plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) TPRC’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax TPRC signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇/ 4/6/2020 ▇/ 3/10/14 ▇▇▇ ▇▇▇▇▇ DATE Chief Executive Officer Tampa Pain Relief Centers, Inc. /▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇/ _ 3/16/2020_ ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE for Tampa Pain Relief Centers, Inc. ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇, ▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇-▇▇▇▇ Will & ▇/▇▇▇▇ LLP Counsel ▇. ▇▇/ 03/06/2020 ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Halifax Legal Affairs Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇ Berlin/_ 3/5/2020 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ BERLIN DATE Assistant Inspector General for Legal Affairs Senior Counsel Administrative and Civil Remedies Branch Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ Gamma and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxGamma’s obligations under this CIA based on a certification by Halifax Gamma that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Gamma is relieved of its CIA obligations, Halifax will Gamma shall be required to notify OIG in writing at least 30 days in advance if Halifax Gamma plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Gamma’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Gamma signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇▇▇▇▇▇ President of Gamma Healthcare, Inc. DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. & ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Gamma Healthcare, Inc. DATE /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇Re/ 04/09/2018 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 4/3/2018 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA. A. IRO Engagement‌ 1. Gamma shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.7 of the CIA or any additional information submitted by Gamma in response to a request by OIG, whichever is later, OIG will notify Gamma if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Gamma may continue to engage the IRO.‌ 2. If Gamma engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Gamma shall submit the information identified in Section V.A.7 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Gamma at the request of OIG, whichever is later, OIG will notify Gamma if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Gamma may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax CHSI and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxCHSI’s obligations under this CIA based on a certification by Halifax CHSI that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax CHSI is relieved of its CIA obligations, Halifax CHSI will be required to notify OIG in writing at least 30 days in advance if Halifax CHSI plans to resume providing health care items or services that are billed to any Federal health care program or to Community Health Systems, Inc. Corporate Integrity Agreement, Amended obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax CHSI signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Community Health /▇Systems, Inc. Corporate Integrity Agreement, Amended /s/ ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇ September 20, 2018 ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /CHSI Senior Vice President, Corporate Compliance and Privacy Officer /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ September 21, 2018 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Counsel for ▇▇▇▇ ▇▇▇▇▇▇▇, Russell, Englert, Orseck, Untereiner & Sauber LLP /s/ ▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ September 21, 2018 ▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Counsel for ▇▇▇▇ ▇▇▇▇▇▇▇, Russell, Englert, Orseck, Untereiner & Sauber LLP /s/ ▇▇▇▇ Re September 21, 2018 ▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services //s/ ▇▇▇▇▇▇ ▇. ▇▇▇ ▇▇▇▇▇ September 21, 2018 ▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇ ▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services Service This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ▇▇▇▇▇▇▇▇ and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of ▇▇▇▇▇▇▇▇; B. This CIA shall become final and binding on the date the final signature is obtained on the CIA.; B. C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.; C. D. OIG may agree to a suspension of Halifax’s ▇▇▇▇▇▇▇▇’▇ obligations under this CIA based on a certification by Halifax ▇▇▇▇▇▇▇▇ that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax ▇▇▇▇▇▇▇▇ is relieved of its CIA obligations, Halifax ▇▇▇▇▇▇▇▇ will be required to notify OIG in writing at least 30 days in advance if Halifax ▇▇▇▇▇▇▇▇ plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. E. The undersigned Halifax ▇▇▇▇▇▇▇▇ signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇ ▇▇▇▇▇▇▇/ ▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇ President ▇▇▇▇ ▇▇▇▇▇▇ Laboratories, Inc. 3/23/2012 DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇▇ ▇▇▇▇▇▇▇/ ▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ Sole Shareholder ▇▇▇▇▇▇▇▇ Laboratories, Inc. 3/23/2012 DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/▇▇▇▇▇▇▇, LLP Counsel for ▇▇▇▇▇▇▇▇ Laboratories, Inc. 3/23/2012 DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Associate Counsel Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services 3/27/2012 DATE /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ Berlin/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ BERLIN Senior Counsel Office of Inspector General U. S. Department of Health and Human Services 3/27/2012 DATE This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax SpecialCare and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxSpecialCare’s obligations under this CIA based on a certification by Halifax SpecialCare that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax SpecialCare is relieved of its CIA obligations, Halifax SpecialCare will be required to notify OIG in writing at least 30 days in advance if Halifax SpecialCare plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax SpecialCare signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 Dec 8/2014 ▇▇▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health SpecialCare Hospital Management Corporation /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 12/10/2014 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE The Law Office of ▇▇▇▇ ▇. ▇▇▇▇▇▇▇, P.C. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 12/10/2014 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center LLP /▇. ▇▇▇▇▇ ▇▇▇▇▇▇/ Dec 8/2014 ▇▇▇▇▇▇ ▇▇▇▇▇▇ DATE /▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 12/10/2014 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE The Law Office of ▇▇▇▇ ▇. ▇▇▇▇▇▇▇, P.C. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 12/10/2014 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 12/23/2014 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 12/23/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax UHS and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxUHS’s obligations under this CIA based on a certification by Halifax UHS that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax UHS is relieved of its CIA obligations, Halifax will UHS shall be required to notify OIG in writing at least 30 days in advance if Halifax UHS plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) UHS’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax UHS signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇/s/ M▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇ July 6, 2020 M▇▇ ▇▇▇▇▇▇ DATE Vice President & and Chief Executive Compliance Officer Halifax Universal Health /Services /s/ J▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇ July 6, 2020 J▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior G▇▇▇▇▇, D▇▇▇ & C▇▇▇▇▇▇▇ LLP Counsel for UHS /s/ L▇▇▇ ▇. Re June 26, 2020 L▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services //s/ K▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇ July 6, 2020 K▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax PharMerica and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxPharMerica’s obligations under this CIA based on a certification by Halifax PharMerica that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax PharMerica is relieved of its CIA obligations, Halifax PharMerica will be required to notify OIG in writing at least 30 days in advance if Halifax PharMerica plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax PharMerica signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 5/11/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Senior Vice President & General Counsel PharMerica Corporation /▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇/ 5/11/15 ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇ & ▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health to PharMerica Corporation /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 5/7/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 5-7-15 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Southern States and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by prior written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s Southern States’ obligations under this CIA based on a certification by Halifax Southern States that it is no longer providing health care items or services that will be billed to any Federal health care program programs and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax Southern States is relieved of its CIA obligations, Halifax will Southern States shall be required to notify OIG in writing at least 30 days in advance if Halifax Southern States plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, the OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to, and do not affect (1) Southern States’ responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable program requirements. E. The undersigned Halifax Southern States signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ Owner _8/27/14 DATE Dobson, Jones, Ball, ▇▇▇▇▇▇/ 3/10/14 ▇▇ & Bridges, P.A. DATE Counsel for Southern States Physical Medicine and Rehabilitation, LLC DATE Dobson, Jones, Ball, ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /Bridges, P.A. Counsel for ▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax SDNA and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxSDNA’s obligations under this CIA based on a certification by Halifax SDNA that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax SDNA is relieved of its CIA obligations, Halifax will SDNA shall be required to notify OIG in writing at least 30 days in advance if Halifax SDNA plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) SDNA’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax SDNA signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 8/2/2016 ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. 8/2/2016 ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇, ESQ. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Good Shepherd and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxGood Shepherd’s obligations under this CIA based on a certification by Halifax Good Shepherd that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Good Shepherd is relieved of its CIA obligations, Halifax Good Shepherd will be required to notify OIG in writing at least 30 days in advance if Halifax Good Shepherd plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax Good Shepherd signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 1/29/2015 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center President Good Shepherd Hospice, Mid America, Inc. /▇. ▇▇▇▇▇ ▇▇▇▇▇▇/ 1/29/15 ▇▇/ 3/10/14 ▇. ▇▇▇ ▇▇▇▇▇▇ DATE ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP PLLC Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Good Shepherd Hospice, Mid America, Inc. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 2/6/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 1-29-15 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ PCMC and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxPCMC’s obligations under this CIA based on a certification by Halifax PCMC that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax PCMC is relieved of its CIA obligations, Halifax will PCMC shall be required to notify OIG in writing at least 30 days in advance if Halifax PCMC plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) PCMC’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax PCMC signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇▇/ ▇▇. ▇▇▇▇▇▇▇ DATE President & ▇▇▇▇▇▇▇ Chief Executive Officer Halifax Pine Creek Medical Center 11-9-17 DATE /▇▇▇▇ ▇▇▇▇▇/ ▇▇▇▇ ▇. ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇ & ▇▇▇▇▇▇, LLP Counsel for Pine Creek Medical Center, LLC 11/9/17 DATE /▇▇▇▇ ▇. Re/ 11/15/17 ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 11/16/2017 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌‌‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. PCMC shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by PCMC in response to a request by OIG, whichever is later, OIG will notify PCMC if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, PCMC may continue to engage the IRO.‌ 2. If PCMC engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, PCMC shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by PCMC at the request of OIG, whichever is later, OIG will notify PCMC if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, PCMC may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ CHSI and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxCHSI’s obligations under this CIA based on a certification by Halifax CHSI that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax CHSI is relieved of its CIA obligations, Halifax CHSI will be required to notify OIG in writing at least 30 days in advance if Halifax CHSI plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax CHSI signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. ON BEHALF OF CHSI‌ /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇9/20/2018 ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /CHSI ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Counsel for ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will , Russell, Englert, Orseck, Untereiner & ▇▇▇▇▇ Sauber LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 9/21/18 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE DATE‌ Counsel for ▇▇▇▇ ▇▇▇▇▇▇▇, Russell, Englert, Orseck, Untereiner & Sauber LLP /▇▇▇▇ ▇. Re/ ▇▇▇▇ RE Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health and Human Services 9/21/2018 DATE /▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇/ 9/21/2018 ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ DATE Senior Counsel Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. CHSI shall engage an IRO to perform the Unallowable Cost Review and the Claims Review that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the reviews in a professionally independent and objective fashion, as set forth in Paragraph E.‌ 2. CHSI shall also engage an IRO to perform the Arrangements Review that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall not have a prohibited relationship to CHSI as set forth in Paragraph F.‌ 3. Within 30 days after OIG receives the information identified in Section‌ V.A.12 of the CIA or any additional information submitted by CHSI in response to a request by OIG, whichever is later, OIG will notify CHSI if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, CHSI may continue to engage the IRO. 4. If CHSI engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, CHSI shall submit the information identified in Section V.A.12 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by CHSI at the request of OIG, whichever is later, OIG will notify CHSI if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, CHSI may continue to engage the IRO.

EFFECTIVE AND BINDING AGREEMENT. Halifax Gardi and OIG agree as follows: A. This CIA IA shall become final and binding on the date the final signature is obtained on the CIAIA. B. This CIA IA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIAIA. C. OIG may agree to a suspension of HalifaxGardi’s obligations under this CIA IA based on a certification by Halifax Gardi that it he is no longer providing health care items or services that will be billed to any Federal health care program and that it he does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Gardi is relieved of its CIA his IA obligations, Halifax will Gardi shall be required to notify OIG in writing at least 30 days in advance if Halifax Gardi plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA IA will be reactivated or modified. D. All requirements and remedies set forth in this IA are in addition to and do not affect: (1) Gardi’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax signatories represent Gardi signatory represents and warrant warrants that they are he is authorized to execute this CIAIA. The undersigned OIG signatories represent that they are signing this CIA IA in their official capacity and that they are authorized to execute this CIAIA. E. F. This CIA IA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIAIA. Facsimiles Electronically transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIAIA. ▇▇▇▇▇▇ ▇. ▇▇▇▇▇ DATE /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 . Re/ _ 05/14/2020 ▇▇▇▇ ▇▇▇▇▇▇ . RE DATE President & Chief Executive Officer Halifax Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇5/15/2020_ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.C of the CIAIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Health Quest and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxHealth Quest’s obligations under this CIA based on a certification by Halifax Health Quest that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax Health Quest is relieved of its CIA obligations, Halifax will Health Quest shall be required to notify OIG in writing at least 30 days in advance if Halifax Health Quest plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Health Quest’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Health Quest signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. Electronically-transmitted /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇/ ▇▇▇▇▇/ 3/10/14 ▇▇▇▇.▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇▇ ▇. B':'▇▇▇▇▇▇▇▇ DATE Senior Counsel V Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA. A. IRO Engagement 1. Health Quest shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.7 of the CIA or any additional information submitted by Health Quest in response to a request by OIG, whichever is later, OIG will notify Health Quest if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Health Quest may continue to engage the IRO. 2. If Health Quest engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Health Quest shall submit the information identified in Section V.A.7 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Health Quest at the request of OIG, whichever is later, OIG will notify Health Quest if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Health Quest may continue to engage the IRO.

EFFECTIVE AND BINDING AGREEMENT. Halifax SPD and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG ▇. ▇▇▇ may agree to a suspension of HalifaxSPD’s obligations requirements under this CIA based on a certification by Halifax SPD that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax SPD is relieved of its CIA obligationsrequirements, Halifax will SPD shall be required to notify OIG in writing at least 30 days in advance if Halifax SPD plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) SPD’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax SPD signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇President Cardinal Health 108, LLC _ Jan 18, 2022_ DATE ▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP DAY Counsel for Halifax Cardinal Health 108, LLC DATE /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇_ 01/21/2022 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ ▇▇▇▇▇▇▇▇▇ and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxNorthwell’s obligations under this CIA based on a certification by Halifax Lenox Hill that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Northwell is relieved of its CIA obligations, Halifax will Northwell shall be required to notify OIG in writing at least 30 days in advance if Halifax Lenox ▇▇▇▇ plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Northwell’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Northwell signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. ON BEHALF OF NORTHWELL HEALTH, INC.‌ /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇/ 12/10/2019 ‌‌ ▇/ 3/10/14 ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE Senior Vice President and General Counsel Halifax Hospital Medical Center Northwell Health, Inc. /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 12/10/2019 ‌‌ ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Ropes & Gray LLP Counsel for Northwell Health, Inc. and Lenox Hill Hospital /▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ DATE‌ Senior Vice President and General Counsel Lenox Hill Hospital /▇▇▇▇▇▇▇ ▇▇▇▇▇▇/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE‌ Ropes & Gray LLP Counsel for Northwell Health, Inc. and Lenox Hill Hospital ___/▇▇▇▇ ▇. ▇▇/_________________________ 12/20/2019 ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services __/▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇/____________________ __12/23/19_______________ ▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. ▇▇▇▇▇▇▇▇▇ shall engage an IRO to perform the Arrangements Review that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall not have a prohibited relationship to ▇▇▇▇▇▇▇▇▇, as set forth in Paragraph E. 2. Within 30 days after OIG receives the information identified in Section‌ V.A.8 of the CIA or any additional information submitted by ▇▇▇▇▇▇▇▇▇ in response to a request by OIG, whichever is later, OIG will notify Northwell if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, ▇▇▇▇▇▇▇▇▇ may continue to engage the IRO. 3. If ▇▇▇▇▇▇▇▇▇ engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, ▇▇▇▇▇▇▇▇▇ shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by ▇▇▇▇▇▇▇▇▇ at the request of OIG, whichever is later, OIG will notify Northwell if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, ▇▇▇▇▇▇▇▇▇ may continue to engage the IRO.

EFFECTIVE AND BINDING AGREEMENT. Halifax 21st Century and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax21st Century’s obligations under this CIA based on a certification by Halifax 21st Century that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax 21st Century is relieved of its CIA obligations, Halifax will 21st Century shall be required to notify OIG in writing at least 30 days in advance if Halifax 21st Century plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) 21st Century’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax 21st Century signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health //s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇, MD 12/16/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, MD DATE Chief Executive Officer 21st Century Oncology, LLC /s/ ▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ 12/15/2015 ▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ DATE K&L Gates LLP Counsel for 21st Century Oncology, LLC /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ 12/16/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services //s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ 12/16/15 ▇/ 3/9/2014 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Consistent with the provisions in the Settlement Agreement pursuant to which this CIA is entered, and into which this CIA is incorporated, Rotech and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of Rotech; B. This CIA shall become final and binding on the date the final signature is obtained on the CIA.; B. This C. Any modifications to this CIA constitutes shall be made with the complete agreement between the parties and may not be amended except by prior written consent of the parties to this CIA.; C. D. OIG may agree to a suspension of Halifax’s Rotech's obligations under this the CIA based on a certification by Halifax that it is no longer providing health care items or services that will be billed to any in the event of Rotech's cessation of participation in Federal health care program and that it does not have any ownership or control interest, as defined programs. If Rotech withdraws from participation in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax programs and is relieved of from its CIA obligationsobligations by the OIG, Halifax will be required Rotech agrees to notify OIG in writing at least 30 days in advance if Halifax plans of Rotech's intent to resume providing health care items reapply as a participating Rotech or services that are billed to any supplier with the Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care programprograms. At Upon receipt of such timenotification, OIG shall will evaluate whether the CIA will should be reactivated or modified. D. E. The undersigned Halifax Rotech signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. This CIA may be executed in counterparts, each . Rotech Corporate Integrity Agreement On Behalf of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /Rotech Medical Corporation /s/ ▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ 2/11/02 -------------------------- ------- ▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE President and CEO Rotech Medical Corporation /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ 1/7/02 -------------------------- ------- ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇ & ▇▇▇▇▇▇▇ Rotech Corporate Integrity Agreement On Behalf of the Office of Inspector General Of the Department of Health and Human Services --------------------------------------------- ---- ▇▇▇▇▇ ▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.Rotech Corporate Integrity Agreement

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ HealthNet and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxHealthNet’s obligations under this CIA based on a certification by Halifax HealthNet that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax HealthNet is relieved of its CIA obligations, Halifax will HealthNet shall be required to notify OIG in writing at least 30 days in advance if Halifax HealthNet plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) HealthNet’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax HealthNet signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇/ _ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ President/CEO HealthNet, Inc. 4/21/17 DATE President & Chief Executive Officer Halifax Health /▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health HealthNet, Inc. 4/21/17 DATE /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 . Re/ 4/26/17 ▇▇▇▇ ▇▇▇▇▇▇ . RE DATE President & Chief Executive Officer Halifax Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health and Human Services /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 4/27/17 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Consistent with the provisions in the Settlement Agreement pursuant to which this CIA is entered, and into which this CIA is incorporated, HealthSouth and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of HealthSouth; B. This CIA shall become final and binding on the date the final signature is obtained on the CIA.; B. This C. Any modifications to this CIA constitutes shall be made with the complete agreement between the parties and may not be amended except by prior written consent of the parties to this CIA.; C. D. OIG may agree to a suspension of HalifaxHealthSouth’s obligations under this the CIA based on a certification by Halifax that it is no longer providing health care items or services that will be billed to any in the event of HealthSouth’s cessation of participation in Federal health care program programs. If HealthSouth withdraws from participation in Federal health care programs and that it does not have any ownership is relieved of its CIA obligations by OIG, HealthSouth shall notify OIG at least 30 days in advance of HealthSouth’s intent to reapply as a participating provider or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills supplier with any Federal health care program. If Halifax is relieved Upon receipt of its CIA obligations, Halifax will be required to notify OIG in writing at least 30 days in advance if Halifax plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such timenotification, OIG shall evaluate whether the CIA will should be reactivated or modified.. Corporate Integrity Agreement HealthSouth Corporation D. E. The undersigned Halifax signatories represent HealthSouth signatory represents and warrant warrants that they are he is authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇Corporate Integrity Agreement HealthSouth Corporation /s/ J▇▇▇ ▇▇▇▇▇▇ 12-30-04 DATE J▇/ 3/10/14 ▇▇ ▇▇▇▇▇▇ Executive Vice President and Chief Compliance Officer Corporate Integrity Agreement HealthSouth Corporation /s/ L▇▇▇▇ ▇▇▇▇▇▇ 12/30/04 DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 L▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant to the Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services Corporate Integrity Agreement HealthSouth Corporation This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ BMG and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxBMG’s obligations under this CIA based on a certification by Halifax BMG that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax BMG is relieved of its CIA obligations, Halifax will BMG shall be required to notify OIG in writing at least 30 days in advance if Halifax BMG plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modifiedmodified.‌‌ D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) BMG’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. D. E. The undersigned Halifax BMG signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. ON BEHALF OF BEAVER MEDICAL GROUP, L.P.‌‌ /▇▇▇▇▇▇▇ ▇▇▇▇/ December 26, 2019 ‌‌ The Beaver Medical Clinic Incorporated, DATE as general partner ▇▇▇▇▇▇▇ ▇▇▇▇, M.D., President /▇▇▇▇▇▇▇ ▇▇▇▇/ December 26, 2019 ‌‌ ▇▇▇▇▇▇▇ ▇▇▇▇, M.D., President DATE _/▇▇▇▇ ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ December 26, 2019 ‌‌ EPIIC Management, Inc., DATE President & Chief Executive Officer Halifax Health /▇as general partner ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇, President/C.E.O. /▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. / December 26, 2019 ‌‌ ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. , President/C.E.O. DATE /▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. December 26, 2019 ‌‌ ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ , President/C.E.O. DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL‌‌ /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇Re/ 12/27/19 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 12/27/19 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA. A. IRO Engagement‌ 1. BMG shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.7 of the CIA or any additional information submitted by BMG in response to a request by OIG, whichever is later, OIG will notify BMG if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, BMG may continue to engage the IRO.‌ 2. If BMG engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, BMG shall submit the information identified in Section V.A.7 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by BMG at the request of OIG, whichever is later, OIG will notify BMG if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, BMG may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax Par and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of Par. B. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. D. OIG may agree to a suspension of HalifaxPar’s obligations under this CIA based on a certification by Halifax Par that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Par is relieved of its CIA obligations, Halifax Par will be required to notify OIG in writing at least 30 days in advance if Halifax Par plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. E. The undersigned Halifax Par signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. Par Corporate Integrity Agreement /▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health Par Pharmaceutical Companies, Inc. 2/28/2013 DATE /▇▇▇▇ ▇▇▇▇▇▇▇▇, III/ ▇▇▇▇ ▇▇▇▇▇▇▇▇, III Counsel Par Pharmaceutical Companies, Inc. 2/28/2013 DATE Par Corporate Integrity Agreement /▇▇▇▇▇▇ ▇▇▇▇▇▇▇/ ▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services 3/1/2013 DATE /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services 3/4/2013 DATE /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/10/2014 3/4/2013 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services DATE Par Corporate Integrity Agreement This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ▇▇▇▇▇▇ and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax▇▇▇▇▇▇’s obligations under this CIA based on a certification by Halifax ▇▇▇▇▇▇ that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax ▇▇▇▇▇▇ is relieved of its CIA obligations, Halifax Balboa will be required to notify OIG in writing at least 30 days in advance if Halifax Balboa plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) ▇▇▇▇▇▇’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax ▇▇▇▇▇▇ signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 4/22/15 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health Balboa Ambulance Services, Inc. /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/10/14 4/22/2015 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ , LLP Counsel for Halifax Health Balboa Ambulance Services, Inc. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 4/24/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/2014 4/21/2015 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Associate Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Consistent with the provisions in the Settlement Agreement pursuant to which this CIA is entered, and into which this CIA is incorporated, PharMerica and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of PharMerica, Inc. and PharMerica Drug Systems, Inc.; B. This CIA shall become final and binding on the date the final signature is obtained on the CIA.; B. This C. Any modifications to this CIA constitutes shall be made with the complete agreement between the parties and may not be amended except by prior written consent of the parties to this CIA.; C. D. OIG may agree to a suspension of HalifaxPharMerica’s obligations under this the CIA based on a certification by Halifax that it is no longer providing health care items or services that will be billed to any in the event of PharMerica’s cessation of participation in Federal health care program programs. If PharMerica withdraws from participation in Federal health care programs and that it does not have any ownership is relieved of its CIA obligations by OIG, PharMerica shall notify OIG at least 30 days in advance of PharMerica’s intent to reapply as a participating provider or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills supplier with any Federal health care program. If Halifax is relieved Upon receipt of its CIA obligations, Halifax will be required to notify OIG in writing at least 30 days in advance if Halifax plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such timenotification, OIG shall evaluate whether the CIA will should be reactivated or modified. D. E. The undersigned Halifax signatories of PharMerica, Inc. and PharMerica Drug Systems, Inc. represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. This CIA may be executed in counterparts. ON BEHALF OF PHARMERICA, each of which constitutes an original and all of which constitute one and the same CIAINC. Facsimiles of signatures shall constitute acceptableAND PHARMERICA DRUG SYSTEMS, binding signatures for purposes of this CIAINC. /▇-▇▇-▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /and C.E.O. PharMerica, Inc. and PharMerica Drug Systems, Inc. 3/29/05 ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇, Esq. DATE Counsel PharMerica, Inc. and PharMerica Drug Systems, Inc. ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant to the Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services Date: Contractor Deposit Control # Date of Deposit: Contractor Contact Name: Phone # Contractor Address: Contractor Fax: PROVIDER/▇▇▇▇▇ ▇PHYSICIAN/SUPPLIER NAME ADDRESS PROVIDER/PHYSICIAN/SUPPLIER # CHECK NUMBER # CONTACT PERSON: PHONE # AMOUNT OF CHECK $ CHECK DATE For each Claim, provide the following: Patient Name HIC # Medicare Claim Number Claim Amount Refunded $ Reason Code for Claim Adjustment: (Select reason code from list below. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇Use one reason per claim) (Please list all claim numbers involved. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health Attach separate sheet, if necessary) Cost Report Year(s) (If multiple cost report years are involved, provide a breakdown by amount and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIAcorresponding cost report year.)

EFFECTIVE AND BINDING AGREEMENT. Halifax CVS Caremark and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of CVS Caremark. B. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. D. OIG may agree to a suspension of HalifaxCVS Caremark’s obligations under this CIA based on a certification by Halifax CVS Caremark that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax CVS Caremark is relieved of its CIA obligations, Halifax CVS Caremark will be required to notify OIG in writing at least 30 days in advance if Halifax CVS Caremark plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. E. The undersigned Halifax CVS Caremark signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇3/24/14 ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇ DATE Chief Compliance Officer CVS Caremark Corporation /▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 3/24/14 ▇. ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇ & ▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health CVS Caremark Corporation /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 3/25/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/9/2014 3/25/14 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 3/25/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Corporate Integrity Agreement 33 This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax LHC and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of LHC. B. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. D. OIG may agree to a suspension of HalifaxLHC’s obligations under this CIA based on a certification by Halifax LHC that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax LHC is relieved of its CIA obligations, Halifax LHC will be required to notify OIG in writing at least 30 days in advance if Halifax LHC plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. E. The undersigned Halifax LHC signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. NOVEMBER DATE Executive VP/General Counsel LHC Group, Inc. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior & Bird LLP Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /for LHC Group, Inc. ▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇ Assistance Inspector General for Legal Affairs DATE Office of Inspector General U. S. Department of Health and Human Services ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇▇ DATE Associate Counsel DATE Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ▇▇▇▇▇ and OIG agree as follows: A. This CIA IA shall become final and binding on the date the final signature is obtained on the CIAIA. B. This CIA IA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIAIA. C. OIG may agree to a suspension of HalifaxKelly’s obligations under this CIA IA based on a certification by Halifax ▇▇▇▇▇ that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax ▇▇▇▇▇ is relieved of its CIA IA obligations, Halifax will ▇▇▇▇▇ shall be required to notify OIG in writing at least 30 days in advance if Halifax ▇▇▇▇▇ plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA IA will be reactivated or modified. D. All requirements and remedies set forth in this IA are in addition to and do not affect (1) Kelly’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax ▇▇▇▇▇ signatories represent and warrant that they are authorized to execute this CIAIA. The undersigned OIG signatories represent that they are signing this CIA IA in their official capacity and that they are authorized to execute this CIAIA. E. F. This CIA IA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIAIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇IA. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇, M.D. DATE /▇▇/ 3/10/14 ▇▇▇ ▇▇▇▇▇▇/_ 08/25/20_ _ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Counsel for ▇▇▇▇▇ /▇▇▇▇ ▇. Re/ 09/08/2020_ ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health and Human Services ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIAIA. A. IRO Engagement 1. ▇▇▇▇▇ shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.4 of the IA or any additional information submitted by ▇▇▇▇▇ in response to a request by OIG, whichever is later, OIG will notify ▇▇▇▇▇ if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, ▇▇▇▇▇ may continue to engage the IRO. 2. If ▇▇▇▇▇ engages a new IRO during the term of the IA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, ▇▇▇▇▇ shall submit the information identified in Section V.A.4 of the IA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by ▇▇▇▇▇ at the request of OIG, whichever is later, OIG will notify ▇▇▇▇▇ if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, ▇▇▇▇▇ may continue to engage the IRO.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ Sava and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxSava’s obligations under this CIA based on a certification by Halifax Sava that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax Sava is relieved of its CIA obligations, Halifax will Sava shall be required to notify OIG in writing at least 30 days in advance if Halifax Sava plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Sava’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Sava signatories represent and warrant that they are authorized to execute this CIACIA . The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇ ▇. Roles/ May 12, 2021 ▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇. Roles Chief Executive Officer DATE /▇▇▇▇ ▇. Re/ 5/13/21 ▇▇▇▇ ▇. RE DATE President & Chief Executive Officer Halifax Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇▇ ▇▇▇▇▇/ 5/13/21 ▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ DATE General Senior Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇5/21/21 _ _ ▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇Services 1. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office Under the Monitor’s subcontract with a data analysis expert, as required by Section III.D of Counsel the CIA, the data analysis expert shall provide, at a minimum, the following reports to the Inspector General U.S. Department of Health Monitor and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel Sava on a quarterly basis: a. Facility Reports: a summary report for Sava, showing facility-level quality indicator (QI) values and information on the MDS assessments underlying these values.‌ b. Facility Comparison Reports: a summary table that includes QI values for each facility covered by the CIA and allows Sava to compare the QI values among the facilities.‌ c. Peer Comparison Reports: a summary report comparing Sava’s QI values to the Inspector General U.S. Department QI values of Health an appropriate peer comparison group.‌ d. Resident Reports: if the data is available to the data analysis expert, a resident-level report showing which QI values were triggered by each resident in the Facility Report.‌ 2. The data analysis expert will provide the Monitor with a QI User Guide, which will describe the format and Human Services contents of the reports listed above and provide QI definitions in terms of the underlying MDS assessment items. APPENDIX B INDEPENDENT REVIEW ORGANIZATION‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA. A. IRO Engagement‌ 1. Sava shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.9 of the CIA or any additional information submitted by Sava in response to a request by OIG, whichever is later, OIG will notify Sava if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Sava may continue to engage the IRO.‌ 2. If Sava engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Sava shall submit the information identified in Section V.A.9 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Sava at the request of OIG, whichever is later, OIG will notify Sava if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Sava may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax Good Shepherd and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxGood Shepherd’s obligations under this CIA based on a certification by Halifax Good Shepherd that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Good Shepherd is relieved of its CIA obligations, Halifax Good Shepherd will be required to notify OIG in writing at least 30 days in advance if Halifax Good Shepherd plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax Good Shepherd signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 1/29/2015 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center Manager Good Shepherd Hospice, Wichita, L.L.C. /▇. ▇▇▇▇▇ ▇▇▇▇▇▇/ 1/29/2015 ▇▇/ 3/10/14 ▇. ▇▇▇ ▇▇▇▇▇▇ DATE ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP PLLC Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Good Shepherd Hospice, Wichita, L.L.C. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 2/6/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 1-29-15 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ▇▇▇▇▇ and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxSaber’s obligations under this CIA based on a certification by Halifax Saber that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Saber is relieved of its CIA obligations, Halifax will Saber shall be required to notify OIG in writing at least 30 days in advance if Halifax Saber plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Saber’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Saber signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 03/30/2020 ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center President ▇▇▇▇▇ /▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. /_ _ March 30, 2020 ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇ & ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP PLC Counsel for Halifax Health Saber ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌ /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇_ 03/31/2020 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇/_ _ 03/31/2020 ▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax The Friendship Entities and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s the Friendship Entities’ obligations under this CIA based on a certification by Halifax the Friendship Entities that it is they are no longer providing health care items or services that will be billed to any Federal health care program and that it does they do not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax is the Friendship Entities are relieved of its their CIA obligations, Halifax will the Friendship Entities shall be required to notify OIG in writing at least 30 days in advance if Halifax plans the Friendship Entities plan to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) the Friendship Entities’ responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax the Friendship Entities signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. DATE DATE DATE DATE DATE /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇/ Friendship Residential Services, Inc. DATE 6-1-15 Owner of Friendship Home Health, Inc.; Friendship Home Health Agency, LLC; Friendship Home Healthcare, Inc.; Friendship Healthcare Systems, Inc.; Friendship HealthCare System; Friendship Home Solutions, Inc.; Friendship – Angel DME, Inc.; Friendship Private Duty, Inc.; Angel Private Duty and Home Health, Inc.; Friendship Home Solutions of New Jersey, Inc.; Friendship Residential Services, Inc. ▇/ 3/10/14 ▇▇▇ & ▇▇▇▇▇▇▇, PLC Counsel for Friendship Home Health, Inc.; Friendship Home Health Agency, LLC; Friendship Home Healthcare, Inc.; Friendship Healthcare Systems, Inc.; Friendship HealthCare System; Friendship Home Solutions, Inc.; Friendship – Angel DME, Inc.; Friendship Private Duty, Inc.; Angel Private Duty and Home Health, Inc.; Friendship Home Solutions of New Jersey, Inc.; Friendship Residential Services, Inc. DATE DATE /▇▇▇▇▇▇ ▇. ▇▇▇▇/_ _ ▇▇▇▇▇▇ ▇. ▇▇▇▇ ▇▇▇▇ & ▇▇▇▇▇▇▇, PLC Counsel for ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ DATE ▇▇▇▇ DATE General & ▇▇▇▇▇▇▇, PLC Counsel Halifax Hospital Medical Center /for ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇ ▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇ ▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services 5/29/15 6/1/2015 This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ Springfield and OIG agree as follows: A. This CIA IA shall become final and binding on the date the final signature is obtained on the CIAIA. B. This CIA IA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIAIA. C. OIG may agree to a suspension of HalifaxSpringfield’s obligations under this CIA IA based on a certification by Halifax Springfield that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Springfield is relieved of its CIA IA obligations, Halifax will Springfield shall be required to notify OIG in writing at least 30 days in advance if Halifax Springfield plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA IA will be reactivated or modified. D. All requirements and remedies set forth in this IA are in addition to and do not affect: (1) Springfield’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax signatories represent Springfield signatory represents and warrant warrants that they are he is authorized to execute this CIAIA. The undersigned OIG signatories represent that they are signing this CIA IA in their official capacity and that they are authorized to execute this CIAIA. E. F. This CIA IA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIAIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIAIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇/ ▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ , M.D. Owner, President Springfield Cardiology, Inc. DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ & ▇▇▇▇▇▇ LLP Counsel for Springfield Cardiology, Inc. DATE Senior Counsel /▇▇▇▇ ▇. Re/ 6/05/2019 ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇/ 3/10/2014 5/30/2019 ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.C of the CIAIA. A. IRO Engagement‌ 1. Springfield shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.2 of the IA or any additional information submitted by Springfield in response to a request by OIG, whichever is later, OIG will notify Springfield if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Springfield may continue to engage the IRO.‌ 2. If Springfield engages a new IRO during the term of the IA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Springfield shall submit the information identified in Section V.A.2 of the IA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information, or any additional information submitted by Springfield at the request of OIG, whichever is later, OIG will notify Springfield if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Springfield may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax Consistent with the provisions in the Settlement Agreement pursuant to which this CIA is entered, Pediatrix and the OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of Pediatrix; Pediatrix Medical Group, Inc. Corporate Integrity Agreement B. This CIA shall become final and binding on the date the final signature is obtained on the CIA.; B. This C. Any modifications to this CIA constitutes shall be made with the complete agreement between the parties and may not be amended except by prior written consent of the parties to this CIA.; C. D. The OIG may agree to a suspension of HalifaxPediatrix’s obligations under this the CIA based on a certification by Halifax that it is no longer providing health care items or services that will be billed to any in the event of Pediatrix’s cessation of participation in Federal health care program programs. If Pediatrix withdraws from participation in Federal health care programs and that it does not have any ownership is relieved of its CIA obligations by the OIG, Pediatrix shall notify the OIG at least 30 days in advance of Pediatrix’s intent to reapply as a participating provider or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills supplier with any Federal health care program. If Halifax is relieved Upon receipt of its CIA obligationssuch notification, Halifax will be required to notify OIG in writing at least 30 days in advance if Halifax plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, the OIG shall evaluate whether the CIA will should be reactivated or modified. D. E. The undersigned Halifax Pediatrix signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. This CIA may be executed in counterparts. Pediatrix Medical Group, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇Inc. Corporate Integrity Agreement /s/ T▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /T▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇ Senior Vice President and General Counsel 9/19/06 DATE /s/ R▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇. S▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ R▇▇▇▇▇ ▇. ▇▇▇▇▇ ▇▇. H▇▇▇▇ & H▇▇▇▇▇▇ L.L.P. Counsel for Pediatrix 9/20/06 DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /Pediatrix Medical Group, Inc. Corporate Integrity Agreement /s/ G▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ G▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ 9/18/06 DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services Pediatrix Medical Group, Inc. Corporate Integrity Agreement This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Hill-Rom and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of Hill-Rom. B. This CIA shall become final and binding on the date the final signature is obtained on obtainedon the CIA. B. C. This CIA constitutes the complete agreement between the parties and may not be notbe amended except by written consent of the parties to this CIA. C. D. OIG may agree to a suspension of HalifaxHill-Rom’s obligations under this CIA based on a certification by Halifax Hill-Rom that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Hill-Rom is relieved of its CIA obligations, Halifax Hill-Rom will be required to notify OIG in writing at least 30 days in advance if Halifax Hill-Rom plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. E. The undersigned Halifax Hill-Rom signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. //s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/10/14 ▇ September 20, 2011 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ . ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & , Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ Hill Rom Holdings, Inc. DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇/s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ September 20, 2011 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ DATE Senior Vice President, Corporate Affairs & Chief Legal Officer Hill Rom Holdings, Inc. /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ September 23, 2011 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services //s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇ September 22, 2011 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Hebrew Homes and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s Hebrew Homes’ obligations under this CIA based on a certification by Halifax Hebrew Homes that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Hebrew Homes is relieved of its CIA obligations, Halifax will Hebrew Homes shall be required to notify OIG in writing at least 30 days in advance if Halifax Hebrew Homes plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Hebrew Homes’ responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax Hebrew Homes signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇. ▇▇▇▇/ 3/10/14 ▇6-17-15 ▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Chairman of the Board of Directors Hebrew Homes Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Network, Inc. /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 6/15/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/10/2014 6/18/15 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Associate Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ KRHS and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxKRHS’s obligations under this CIA based on a certification by Halifax KRHS that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax KRHS is relieved of its CIA obligations, Halifax will KRHS shall be required to notify OIG in writing at least 30 days in advance if Halifax KRHS plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) KRHS’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax KRHS signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇/ 3/10/14 September 21, 2018 ‌‌ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health Officer, KRH /▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇September 21, 2018 ‌‌ ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Partner, ▇▇▇▇▇▇▇▇▇ LLP Counsel Halifax Hospital Medical Center for KRH /▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇/ September 21, 2018 ‌‌ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ DATE Chief Executive Officer, KRH /▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. September 21, 2018 ‌‌ ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE Partner, ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health KRH /▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇/ 3/10/14 September 21, 2018 ‌‌ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health Officer, KRH /▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. September 21, 2018 ‌‌ ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE Partner, ▇▇▇▇▇▇▇▇▇ Will & LLP Counsel for KRH /▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇/ September 21, 2018 ‌‌ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ DATE Chief Executive Officer, KRH _/▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ September 21, 2018 ‌‌ ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE Partner, ▇▇▇▇▇▇▇▇▇ LLP Counsel for Halifax Health KRH ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌‌ /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇Re/ 9/24/2018 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 September 22, 2018 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. KRHS shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall not have a prohibited relationship as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by KRHS in response to a request by OIG, whichever is later, OIG will notify KRHS if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, KRHS may continue to engage the IRO.‌ 2. If KRHS engage a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, KRHS shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by KRHS at the request of OIG, whichever is later, OIG will notify KRHS if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, KRHS may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ APM, Park Center, ▇▇▇▇▇▇, and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of Halifax’s APM, Park Center, and ▇▇▇▇▇▇’▇ obligations under this CIA based on a certification by Halifax APM, Park Center, and ▇▇▇▇▇▇ that it is they are no longer providing health care items or services that will be billed to any Federal health care program and that it does do not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax is APM, Park Center, and ▇▇▇▇▇▇ are relieved of its their CIA obligations, Halifax will APM, Park Center, and ▇▇▇▇▇▇ shall be required to notify OIG in writing at least 30 days in advance if Halifax plans APM, Park Center, and ▇▇▇▇▇▇ plan to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) APM, Park Center, and ▇▇▇▇▇▇’▇ responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax APM, Park Center, and ▇▇▇▇▇▇ signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. ▇▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ DATE Principal, Advanced Pain Management And Spine Specialists, P.A. ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ DATE Counsel for Advanced Pain Management Specialists, P.A., d/b/a Advanced Pain Management & Spine Specialists /▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 12/13/18 ‌‌ ▇▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health Principal, Park Center for Procedures, LLC /▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇/ 12/13/18 ‌‌ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ DATE Counsel for Park Center for Procedures, LLC /▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇/ ▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ M.D. DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇/ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇/ 3/10/14 ▇ Counsel for ▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ M.D. DATE ▇▇▇▇ ▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel . RE DATE Assistant Inspector General for Halifax Legal Affairs Office of Inspector General U. S. Department of Health /and Human Services ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ BERLIN DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. APM, Park Center, and ▇▇▇▇▇▇ shall each engage an IRO to perform the Claims Review that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO(s) shall conduct the Claims Review in a professionally independent and objective fashion, as set forth in Paragraph E.‌ 2. APM, Park Center, and ▇▇▇▇▇▇ shall each engage an IRO to perform the Arrangements Review that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO(s) shall not have a prohibited relationship to APM, Park Center, and ▇▇▇▇▇▇ as set forth in Paragraph F.‌ 3. Within 30 days after OIG receives the information identified in Section‌ V.A.8 of the CIA or any additional information submitted by APM, Park Center, and ▇▇▇▇▇▇ in response to a request by OIG, whichever is later, OIG will notify APM, Park Center, and ▇▇▇▇▇▇ if the IRO(s) is/are unacceptable. Absent notification from OIG that an IRO is unacceptable, APM, Park Center, and ▇▇▇▇▇▇ may continue to engage the IRO. 4. If APM, Park Center, and ▇▇▇▇▇▇ engage a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, APM, Park Center, and ▇▇▇▇▇▇ shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by APM, Park Center, and ▇▇▇▇▇▇ at the request of OIG, whichever is later, OIG will notify APM, Park Center, and ▇▇▇▇▇▇ if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, APM, Park Center, and ▇▇▇▇▇▇ may continue to engage the IRO. B. IRO Qualifications Each IRO shall:‌‌ 1. assign individuals to conduct the Arrangements Review who are knowledgeable in the requirements of the Anti-Kickback Statute and the ▇▇▇▇▇ Law and the regulations and other guidance documents related to these statutes;‌ 2. possess expertise in fair market valuation issues or have the ability to associate a valuation firm to assist in conducting the transactions review component of the Arrangements Review;‌ 3. assign individuals to conduct the Claims Review who have expertise in the Medicare and state Medicaid program requirements applicable to the claims being reviewed;‌ 4. assign individuals to design and select the Claims Review sample who are knowledgeable about the appropriate statistical sampling techniques;‌ 5. assign individuals to conduct the coding review portions of the Claims Review who have a nationally recognized coding certification and who have maintained this certification (e.g., completed applicable continuing education requirements);‌‌ 6. assign licensed nurses or physicians with relevant education, training and specialized expertise (or other licensed health care professionals acting within their scope of practice and specialized expertise) to make the medical necessity determinations required by the Claims Review; and‌ 7. have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis.‌ C. IRO Responsibilities Each IRO shall:‌‌ 1. perform each Arrangements Review and Claims Review in accordance with the specific requirements of the CIA;‌ 2. follow all applicable Medicare and state Medicaid program rules and reimbursement guidelines in making assessments in the Claims Review;‌ 3. request clarification from the appropriate authority (e.g., Medicare contractor), if in doubt of the application of a particular Medicare or state Medicaid program policy or regulation;‌‌ 4. respond to all OIG inquires in a prompt, objective, and factual manner; and 5. prepare timely, clear, well-written reports that include all the information required by Appendix B and Appendix C (as applicable) to the CIA. D. APM, Park Center, and ▇▇▇▇▇▇ Responsibilities‌ APM, Park Center, and ▇▇▇▇▇▇ shall ensure that the IRO(s) has/have access to all records and personnel necessary to complete the reviews listed in Section III.E of this CIA and that all records furnished to any IRO are accurate and complete.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ WCH and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxWCH’s obligations under this CIA based on a certification by Halifax WCH that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax WCH is relieved of its CIA obligations, Halifax will WCH shall be required to notify OIG in writing at least 30 days in advance if Halifax WCH plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) WCH’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax WCH signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP AUSTRIA Chief Operating Officer DATE Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ WCH DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. WCH shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by WCH in response to a request by OIG, whichever is later, OIG will notify WCH if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, WCH may continue to engage the IRO.‌ 2. If WCH engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, WCH shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by WCH at the request of OIG, whichever is later, OIG will notify WCH if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, WCH may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ Kumar and OIG agree as follows: A. This CIA IA shall become final and binding on the date the final signature is obtained on the CIAIA. B. This CIA IA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIAIA. C. OIG may agree to a suspension of HalifaxKumar’s obligations under this CIA IA based on a certification by Halifax Kumar that it he is no longer providing health care items or services that will be billed to any Federal health care program and that it he does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax Kumar is relieved of its CIA his IA obligations, Halifax will Kumar shall be required to notify OIG in writing at least 30 days in advance if Halifax Kumar plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA IA will be reactivated or modified. D. All requirements and remedies set forth in this IA are in addition to and do not affect: (1) Kumar’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax signatories represent Kumar signatory represents and warrant warrants that they are he is authorized to execute this CIAIA. The undersigned OIG signatories represent that they are signing this CIA IA in their official capacity and that they are authorized to execute this CIAIA. E. F. This CIA IA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIAIA. Facsimiles Electronically transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /IA.‌‌ ON BEHALF OF ▇▇▇▇▇ ▇▇▇▇▇‌‌ /▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇/ 02/11/2021 ‌‌ ▇▇▇▇▇ ▇▇▇▇▇, M.D. DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /_ _ 02/16/2021 ‌‌ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇ DATE ▇▇▇▇▇▇ & ▇▇▇▇▇▇▇ LLP ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌‌ /▇▇▇▇ ▇. Re/ 02/18/2021_ ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/_ 02/18/2021_ ▇▇▇▇▇ ▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.C of the CIAIA. A. IRO Engagement‌ 1. Kumar shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.2 of the IA or any additional information submitted by Kumar in response to a request by OIG, whichever is later, OIG will notify Kumar if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Kumar may continue to engage the IRO.‌ 2. If Kumar engages a new IRO during the term of the IA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Kumar shall submit the information identified in Section V.A.2 of the IA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information, or any additional information submitted by Kumar at the request of OIG, whichever is later, OIG will notify Kumar if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Kumar may continue to engage the IRO.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax UHS and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxUHS’s obligations under this CIA based on a certification by Halifax UHS that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax UHS is relieved of its CIA obligations, Halifax will UHS shall be required to notify OIG in writing at least 30 days in advance if Halifax UHS plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) UHS’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax UHS signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇July 6, 2020 ▇▇▇ ▇▇▇▇▇▇ DATE Vice President & and Chief Executive Compliance Officer Halifax Universal Health Services‌ /▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 7/6/2020 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇ DATE‌ ▇▇▇▇▇▇, ▇▇▇▇ & ▇. ▇▇▇▇▇▇▇ LLP Counsel for UHS ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌ /▇▇▇▇ ▇. Re/ 06/26/2020 ▇▇▇▇ ▇. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 6 July 2020 ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax SMMC and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxSMMC’s obligations under this CIA based on a certification by Halifax SMMC that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax SMMC is relieved of its CIA obligations, Halifax will SMMC shall be required to notify OIG in writing at least 30 days in advance if Halifax SMMC plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) SMMC’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax SMMC signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇ON BEHALF OF THE COUNTY OF SAN MATEO – SAN MATEO MEDICAL CENTER (SMMC)‌ ▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior County Counsel Office County of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services San Mateo 7/29/2021 APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA. A. IRO Engagement‌ 1. SMMC shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.7 of the CIA or any additional information submitted by SMMC in response to a request by OIG, whichever is later, OIG will notify SMMC if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, SMMC may continue to engage the IRO.‌ 2. If SMMC engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, SMMC shall submit the information identified in Section V.A.7 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by SMMC at the request of OIG, whichever is later, OIG will notify SMMC if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, SMMC may continue to engage the IRO.‌ B. IRO Qualifications The IRO shall:‌‌ 1. assign individuals to conduct the Claims Review who have expertise in the Medicare and state Medicaid program requirements applicable to the claims being reviewed;‌ 2. assign individuals to design and select the Claims Review sample who are knowledgeable about the appropriate statistical sampling techniques;‌ 3. assign individuals to conduct the coding review portions of the Claims Review who have a nationally recognized coding certification and who have maintained this certification (e.g., completed applicable continuing education requirements);‌‌ 4. assign licensed nurses or physicians with relevant education, training and specialized expertise (or other licensed health care professionals acting within their scope‌ of practice and specialized expertise) to make the medical necessity determinations required by the Claims Review; and‌ 5. have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis. C. IRO Responsibilities The IRO shall:‌ 1. perform each Claims Review in accordance with the specific requirements of the CIA;‌ 2. follow all applicable Medicare and state Medicaid program rules and reimbursement guidelines in making assessments in the Claims Review;‌ 3. request clarification from the appropriate authority (e.g., Medicare contractor), if in doubt of the application of a particular Medicare or state Medicaid program policy or regulation;‌‌ 4. respond to all OIG inquires in a prompt, objective, and factual manner; and 5. prepare timely, clear, well-written reports that include all the information required by Appendix B to the CIA. D. SMMC Responsibilities‌ SMMC shall ensure that the IRO has access to all records and personnel necessary to complete the reviews listed in III.D of this CIA and that all records furnished to the IRO are accurate and complete.

EFFECTIVE AND BINDING AGREEMENT. Halifax Extendicare and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of Extendicare. B. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. D. OIG may agree to a suspension of HalifaxExtendicare’s obligations under this CIA based on a certification by Halifax Extendicare that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax Extendicare is relieved of its CIA obligations, Halifax Extendicare will be required to notify OIG in writing at least 30 thirty (30) days in advance if Halifax Extendicare plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. E. The undersigned Halifax Extendicare signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. G. This CIA is by and between the parties hereto. The CIA is not intended to establish any legal rights for or confer any legal rights upon any non- governmental entities or persons not a party to the CIA. The parties agree, however, that this CIA is a public document and it may be admissible in a judicial or administrative proceeding. /▇▇▇ ▇▇▇▇▇▇▇/ 10/2/14 ▇▇▇ ▇▇▇▇▇▇▇ DATE President and Chief Executive Officer Extendicare Health Service, Inc. /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 10/2/14 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ LLP /J. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 10/3/14 J. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇ ▇▇▇▇ LLP /▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇/ 10/2/14 ▇▇▇ ▇▇▇▇▇▇▇ DATE President and Chief Executive Officer Extendicare Health Service, Inc. /▇▇/ 3/10/14 ▇▇▇ ▇. ▇▇▇▇▇▇▇/ 10/2/14 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇ ▇▇▇▇▇▇ Will & ▇▇▇▇▇▇▇ LLP Counsel for Halifax Health //J. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 10/3/14 J. ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇ ▇▇▇ Will & ▇▇▇▇▇▇▇▇ ▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 10/3/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 9/30/14 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Hill-Rom and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of Hill-Rom. B. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. D. OIG may agree to a suspension of HalifaxHill-Rom’s obligations under this CIA based on a certification by Halifax Hill-Rom that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that Hill-Rom Corporate Integrity Agreement bills any Federal health care program. If Halifax Hill-Rom is relieved of its CIA obligations, Halifax Hill-Rom will be required to notify OIG in writing at least 30 days in advance if Halifax Hill- Rom plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. E. The undersigned Halifax Hill-Rom signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent signatory represents that they are he is signing this CIA in their his official capacity and that they are he is authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. Hill-Rom Corporate Integrity Agreement /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇9/20/2011 ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇,Chief Executive Officer Hill Rom Holdings, Inc. DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇▇▇/ 3/7/2014 9/20/2011 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ Vice President, Corporate Affairs & Chief Legal Officer Hill Rom Holdings, Inc. DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services Hill-Rom Corporate Integrity Agreement /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Associate Counsel Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services DATE 9/23/2011 /▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Senior Counsel Office of Inspector General U. S. Department of Health and Human Services DATE 9/22/2011 Hill-Rom Corporate Integrity Agreement APPENDIX A INDEPENDENT REVIEW ORGANIZATION This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax Tri-County and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by prior written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxTri-County’s obligations under this CIA based on a certification by Halifax Tri-County that it is no longer providing health care items or services that will be billed to any Federal health care program programs and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax Tri-County is relieved of its CIA obligations, Halifax will Tri- County shall be required to notify OIG in writing at least 30 days in advance if Halifax Tri- County plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, the OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to, and do not affect (1) Tri-County’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable program requirements. E. The undersigned Halifax Tri-County signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 6-16-14 ▇▇▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health Date Owner, Tri-County Ambulance /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 6-16-14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health Date Owner, Tri-County Ambulance /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 6-16-14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Date Counsel for Halifax Health Tri-County /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 7/25/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. Office of Inspector General U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 7-14-14 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Halifax ‌ GSMC and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxGSMC’s obligations requirements under this CIA based on a certification by Halifax GSMC that it is they are no longer providing health care items or services that will be billed to any Federal health care program and that it does they do not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Halifax GSMC is relieved of its CIA obligationsrequirements, Halifax will GSMC shall be required to notify OIG in writing at least 30 days in advance if Halifax GSMC plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) GSMC’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. E. The undersigned Halifax GSMC signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /▇▇▇▇ CIA.‌‌ ON BEHALF OF ▇▇▇▇▇▇/ 3/10/14 ▇ GOOD SAMARITAN MEDICAL CENTER‌‌ /▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇/_ 4/4/2022 _‌‌ ▇/ 3/10/14 ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ DATE President of ▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Good Samaritan Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇4/4/2022 _‌‌ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇DATE Counsel for ▇▇▇▇▇▇▇ Good Samaritan Medical Center ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES‌‌ /▇▇▇▇ ▇. Re/ 4/8/22 ▇▇▇▇ ▇. RE DATE Senior Counsel Assistant Inspector General for Legal Affairs Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇ ▇. ▇’▇▇▇▇▇/ 04/07/2022 ▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇’▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services APPENDIX A INDEPENDENT REVIEW ORGANIZATION‌‌‌ This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement‌ 1. GSMC shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall not have a prohibited relationship with GSMC as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by GSMC in response to a request by OIG, whichever is later, OIG will notify GSMC if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, GSMC may continue to engage the IRO.‌ 2. If GSMC engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, GSMC shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by GSMC at the request of OIG, whichever is later, OIG will notify GSMC if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, GSMC may continue to engage the IRO.‌ B. IRO Qualifications The IRO shall:‌‌ 1. assign individuals to conduct the Arrangements Review who are knowledgeable in the requirements of the Anti-Kickback Statute and the ▇▇▇▇▇ Law and the regulations and other guidance documents related to these statutes;‌ 2. possess expertise in fair market valuation issues or have the ability to associate a valuation firm to assist in conducting the transactions review component of the Arrangements Review; and‌ 3. have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis.‌

EFFECTIVE AND BINDING AGREEMENT. Halifax ICH and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxICH’s obligations under this CIA based on a certification by Halifax ICH that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax ICH is relieved of its CIA obligations, Halifax ICH will be required to notify OIG in writing at least 30 days in advance if Halifax ICH plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax ICH signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /Seslee ▇. ▇▇▇▇▇▇▇/ 1-16-15 SESLEE ▇. ▇▇▇▇▇▇▇ DATE Counsel for the Hospital Authority of ▇▇▇▇▇ County /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇1-12-15 ▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health Administrator/CEO for ▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ County Hospital DATE General Counsel Halifax Hospital Medical Center /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 1/16/15 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇1/16/15 ▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇/ 3/10/2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇ DATE Associate Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA. A. IRO Engagement 1. ICH shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.9 of the CIA or any additional information submitted by ICH in response to a request by OIG, whichever is later, OIG will notify ICH if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, ICH may continue to engage the IRO. 2. If ICH engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, ICH shall submit the information identified in Section V.A.9 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by ICH at the request of OIG, whichever is later, OIG will notify ICH if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, ICH may continue to engage the IRO.

EFFECTIVE AND BINDING AGREEMENT. Halifax CHSI and OIG agree as follows: A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA. C. OIG may agree to a suspension of HalifaxCHSI’s obligations under this CIA based on a certification by Halifax CHSI that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § §1320a-3, in any entity that bills any Federal health care program. If Halifax CHSI is relieved of its CIA obligations, Halifax CHSI will be required to notify OIG in writing at least 30 days in advance if Halifax CHSI plans to resume providing health care items or services that are billed to any Federal health care program or to Community Health Systems, Inc. Corporate Integrity Agreement obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. D. The undersigned Halifax CHSI signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity capacities and that they are authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. Community Health Systems, Inc. Corporate Integrity Agreement /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ DATE President & Chief Executive Officer Halifax Health /▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 July 23, 2014 ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE General Counsel Halifax Hospital Medical Center Sr. Vice President, Corporate Compliance and Privacy Officer /▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. , Esq./ July 23, ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax Health /▇▇▇▇ ▇▇▇▇▇▇/ 3/10/14 ▇▇▇▇ ▇▇▇▇▇▇ , Esq. DATE President & Chief Executive Officer Halifax Health /▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇/ 3/10/14 ▇. ▇▇▇▇ ▇▇▇▇▇▇▇▇ DATE ▇▇▇▇▇▇▇▇▇ Will & ▇▇▇▇▇ LLP Counsel for Halifax CHSI Community Health Systems, Inc. Corporate Integrity Agreement /▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇/ 3/10/14 7/28/14 ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/9/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services /▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇/ 3/7/2014 ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ DATE Senior Counsel Office of Counsel to the Inspector General U.S. U. S. Department of Health and Human Services /▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇/ 3/10/2014 July 24, 2014 ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ DATE Associate Senior Counsel Office of Counsel to the Inspector General U.S. Department of Health and Human Services Community Health Systems, Inc. Corporate Integrity Agreement This Appendix contains the requirements relating to the Legal Independent Review Organization (Legal IRO) required by Section III.E of the CIA.